Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · IEX Real-Time Price · USD
17.37
-0.25 (-1.42%)
Apr 23, 2024, 4:00 PM EDT - Market closed
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
The company is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc.
Country | United States |
Founded | 2016 |
IPO Date | Mar 12, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 46 |
CEO | Samuel S. Kintz M.B.A. |
Contact Details
Address: 6200 Lookout Road Boulder, Colorado 80301 United States | |
Phone | 720-647-8519 |
Website | enliventherapeutics.com |
Stock Details
Ticker Symbol | ELVN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001672619 |
ISIN Number | US29337E1029 |
Employer ID | 81-1523849 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Samuel S. Kintz M.B.A. | Co-Founder, Chief Executive Officer, Secretary and Director |
Benjamin Hohl | Chief Financial Officer and Head of Corporate Development |
Dr. Helen Louise Collins M.D. | Chief Medical Officer |
Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder, Chief Scientific Officer and Directors |
Anish Patel Pharm.D. | Co-Founder and Chief Operating Officer |
Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer and Head of Business Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Apr 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Apr 15, 2024 | PRE 14A | Other preliminary proxy statements |
Apr 11, 2024 | 144 | Filing |
Apr 11, 2024 | 144 | Filing |
Apr 11, 2024 | 144 | Filing |
Apr 11, 2024 | 144 | Filing |
Apr 11, 2024 | 144 | Filing |
Apr 11, 2024 | 144 | Filing |
Apr 11, 2024 | 144 | Filing |